Novo says diabetes drug Xultophy cost-effective versus insulin intensification treatment
pharmafile | March 2, 2016 | News story | Sales and Marketing | Novo Nordisk, Xultophy, diabetes
Novo Nordisk says findings show its Tresiba and Victoza combo Xultophy (insulin degludec/liraglutide: IDegLira), is cost-effective compared to insulin intensification treatment options for UK type 2 diabetes patients who are uncontrolled on basal insulin.
The company reported health economics and outcomes research findings presented this week at the Diabetes UK Professional Conference in Glasgow, Scotland.
The analysis assessed the cost-effectiveness of Xultophy compared to an up-titration of insulin glargine U100, separate injections of liraglutide added to basal insulin (insulin glargine U100 or insulin detemir), or insulin glargine U100 in combination with three daily injections of insulin aspart (basal-bolus).
“In the UK, 69% of people with type 2 diabetes treated with basal insulin do not achieve glycaemic control”, says Melanie Davies, Professor of Diabetes Medicine, University of Leicester, UK. “It is useful for clinicians that cost-effective combination treatments such as IDegLira are available as they have been shown to help patients achieve optimal glycaemic targets and may help prevent complications.”
On average, in the UK, daily administration of IDegLira cost less in total and was more effective compared to the separate injections of Victoza added to basal insulin or compared to basal-bolus regimens. IDegLira was also cost-effective versus up-titration of insulin glargine U100, with a cost of £6,090 per quality-adjusted life year [QALY] gained, which Novo points out is well below the UK threshold of £20,000 to £30,000 used by NICE.
Patient data for the present analysis were sourced from the DUAL V clinical trial and a pooled analysis study of five completed Novo Nordisk trials in patients with type 2 diabetes inadequately controlled on basal insulin.
Xultophy, which is administered by a single pen, launched in the UK in June 2015.
Joel Levy
Related Content
FDA approves Wegovy for treatment of MASH in adults with liver fibrosis
The US Food and Drug Administration (FDA) has granted accelerated approval for Wegovy (semaglutide) as …
BioMed X and Novo Nordisk partner on oral peptide drug delivery innovation
BioMed X has announced a new collaboration with Novo Nordisk to improve oral delivery of …
MetP Pharma releases positive data on intranasal semaglutide administration
MetP Pharma has released new data highlighting the advantages of its MetP technology in delivering …
